FDA panel to spotlight BiDil

This Thursday an FDA panel will consider whether BiDil -- rejected eight years ago -- should become the first drug approved for one race. The agency panel will review a study of more than 1,000 patients showing that the drug significantly reduced hospitalizations and deaths among African-American heart failure patients. NitroMed says it simply followed the data, but critics contend that the drug raises questions about trial designs and marketing that will be debated for years to come.

- read this article from The New York Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.